



20 **Abstract**

21 Introduction

22 COVID-19 causes global health and psychosocial devastation, particularly to high-risk patients such  
23 as those with neuromuscular diseases (NMDs). The mRNA-based BNT162b2 and inactivated whole-  
24 virus CoronaVac are two novel COVID-19 vaccines widely used across the world that confer immune  
25 protection to healthy individuals. However, hesitancy towards COVID-19 vaccination was common  
26 for patients with NMDs early in the pandemic due to the paucity of data on the safety and efficacy in  
27 this specific patient population. Therefore, we examined the underlying factors associated with vaccine  
28 hesitancy across time for these patients and included the assessment of the reactogenicity and  
29 immunogenicity of these two vaccines.

30

31 Methods

32 Pediatric patients were screened from our NMD registry. For the vaccine hesitancy arm, those aged 8-  
33 18 years with no cognitive delay were invited to complete surveys in January and April 2022. For the  
34 reactogenicity and immunogenicity arm, patients aged 2-21 years were enrolled for COVID-19  
35 vaccination between June 2021 to April 2022. Participants recorded adverse reactions (ARs) for 7 days  
36 after vaccination. Peripheral blood was obtained before BNT162b2 or CoronaVac and within 49 days  
37 after vaccination to measure their serological antibody responses as compared to healthy children and  
38 adolescents.

## 39 Results

40 Forty-one patients completed vaccine hesitancy surveys for both timepoints, and 22 joined our  
41 reactogenicity and immunogenicity arm of the study. Two or more family members vaccinated against  
42 COVID-19 was positively associated with intention of vaccination (odds ratio 11.7, 95% CI 1.81-75.1,  
43  $p=0.010$ ). Pain at the injection site, fatigue and myalgia were the commonest ARs. Most ARs were  
44 mild (75.5%,  $n=71/94$ ). All 19 patients seroconverted against the wildtype SARS-CoV-2 after two  
45 doses of BNT162b2 or CoronaVac, although there was lower neutralization against the Omicron BA.1  
46 variant.

47

## 48 Discussion

49 This study demonstrated vaccine hesitancy amongst patients with NMDs was influenced by family  
50 members and changed across time. BNT162b2 and CoronaVac were safe and immunogenic even for  
51 patients on low-dose corticosteroids. Future research is required to assess the durability of the COVID-  
52 19 vaccines, the effectiveness of booster doses and other routes of administration against emerging  
53 SARS-CoV-2 variants for these patients.

## 54 1 Introduction

55 Since the onset of the COVID-19 pandemic, infection by the SARS-CoV-2 virus has been associated  
56 with significant morbidity, mortality and negative socioeconomic impact throughout the world.(1-3)  
57 Certain patient populations, such as those with neuromuscular disorders (NMDs), have greater risks of  
58 severe disease and death from infections due to their muscle weakness of the chest wall or  
59 diaphragmatic muscle, cardiac involvement and immunosuppressed state.(4) Vaccination is highly  
60 effective against symptomatic infection, hospital admission and severe COVID-19 in healthy adults  
61 and children.(5-10) As such, the mRNA-based BNT162b2 and inactivated whole-virus CoronaVac  
62 vaccines are amongst the most widely used COVID-19 vaccines globally since authorization for  
63 emergency use by World Health Organization.(11-13) Based on these findings in healthy individuals,  
64 several national neurology associations and neuromuscular disease networks recommend COVID-19  
65 vaccination for those with NMDs, but data on this important high-risk patient population specifically  
66 remain scarce.(4)

67 Although COVID-19 vaccination is expected to reduce infectious disease severity in the NMD  
68 population, vaccine hesitancy appears to be a major potential barrier.(14) As example, only 69.0% of  
69 the parents would want their NMD child vaccinated during the early pandemic period in December  
70 2020.(15) It is also concerning that as little as 42.6% of those with Duchenne muscular dystrophy  
71 (DMD) were vaccinated against COVID-19 by November 2021 in Poland.(16) Their reasons for not  
72 opting for vaccination during this early, pre-Omicron variant period included the potential for reduced  
73 efficacy due to their use of immunosuppressive or immunomodulating therapies and uncertainties  
74 regarding possible interactions between the vaccines and treatments for NMDs.(17-19) Despite the  
75 availability of two different COVID-19 vaccine types, BNT162b2 and CoronaVac, in our locality, our  
76 NMD patients also appeared reluctant on vaccination. Some of these patients had cited the risks of  
77 adverse effects, disease complications and reduced efficacy as some of their main concerns.

78 The reason that there has been a paucity of NMD-specific safety and immunogenicity data despite  
79 the rollout of the many types of COVID-19 vaccines is because NMD is a group of rare diseases and  
80 NMD patients are hesitant to volunteer for receiving novel vaccines, and so large-scale studies had not  
81 yet been possible. Therefore, scientific evidence on COVID-19 vaccination in NMD patients have been  
82 based on small cohorts only thus far. For 14 adult NMD patients, BNT162b2 and mRNA-1273 vaccines  
83 seem safe and immunogenic.(20) The mRNA-1273 vaccine achieved robust humoral and cellular  
84 immune responses in 100 adult patients with myasthenia gravis.(21) Unfortunately, there are still no  
85 available safety and immunogenicity data on COVID-19 vaccines in children with NMDs.  
86 Importantly, there has been no previous research on the inactivated COVID-19 vaccines in adult or  
87 pediatric patients with NMDs, including immunogenicity against the novel variants, such as Omicron.

88 Therefore, this study investigated in-depth the underlying reasons and temporal changes in vaccine  
89 hesitancy for pediatric patients with NMDs during the Omicron wave in 2022. Additionally, we  
90 assessed the safety and immunogenicity of BNT162b2 and CoronaVac by recording adverse effects  
91 and measuring serum antibody levels and neutralization against the wild type (WT) SARS-CoV-2 virus  
92 and Omicron B.1.1.529 variant.

## 93 2 Materials and methods

### 94 2.1 Study Population

95 All participants were screened from the Hong Kong (HK) NMD registry.(22) This registry has been  
96 approved by the Institutional Review Board (IRB) and collects patient and clinician-reported  
97 demographic and clinical information from those with confirmed diagnoses of NMDs after their  
98 consent.(22) The diagnosis was determined by clinical pediatric neurologists and supported by genetic  
99 testing and/or muscle biopsy results. The neurology clinical study team is based at HK Children's  
100 Hospital, Duchess of Kent Children's Hospital at Sandy Bay and Queen Mary Hospital that receives  
101 referrals from throughout the entire HK territory for clinical care and research in pediatric NMDs.(22)  
102 Enrolment in the vaccine hesitancy survey arm of the study required patients to be 8-18 years old with  
103 no cognitive delay. In another arm of this study, patients aged 2-21 years were invited for COVID-19  
104 vaccination to study the reactogenicity and immunogenicity of the BNT162b2 and CoronaVac  
105 vaccines. Potential participants needed to be in stable condition. A patient could join either or both  
106 arms of the study, if eligible (Supplementary Figure 1).

### 107 2.2 COVID-19 Vaccine Hesitancy Survey

108 Patients received and completed the first survey through online or phone interviews in January 2022.  
109 The survey was based on our previous publication on 2,609 healthy adolescents, supplemented with  
110 more tailored queries pertinent to NMD patients and younger age groups that were added into this  
111 study.(23) In summary, it included 21 yes/no or multiple-choice questions on patient demographics,  
112 presence of medical complexity, history of past COVID-19 infection, influenza and COVID-19  
113 vaccination, intention of receiving COVID-19 vaccination and the reasons for their choice  
114 (Supplementary file). Concerns about receiving COVID-19 vaccination included perception of risks,  
115 challenges in access to vaccination centers, adverse effects, less efficacy than their healthy counterparts

116 and vaccine-drug interactions that potentially affect their current NMD treatments. The expected time  
117 required to complete the survey was 15 minutes. A follow-up survey was sent to patients in April 2022  
118 to longitudinally assess changes in attitudes, hesitancy and associated reasons shortly after the peak of  
119 the first major COVID-19 wave due to the SARS-CoV-2 Omicron variant in HK.

### 120 **2.3 Reactogenicity and Immunogenicity Study of COVID-19 Vaccines**

121 The reactogenicity and immunogenicity arm is a sub-study under the registered Coronavirus  
122 disease-19 (COVID-19) Vaccination in Adolescents and Children (COVAC) (NCT04800133). The  
123 COVID-19 vaccines were administered at the Community Vaccination Centers research sites  
124 supported by the University of Hong Kong (HKU) and the HK Government's COVID-19 Vaccination  
125 Program. Patients received 2 doses of either BNT162b2 or CoronaVac, given 21 or 28 days apart,  
126 respectively, followed by an option of either vaccine types as a third dose at least 28 days after their  
127 second dose. The dosages of BNT162b2 were 0.3 mL (equivalent to 30 µg of COVID-19 mRNA  
128 vaccine embedded in lipid nanoparticles) for participants aged  $\geq 12$  years. One-third fractional dose of  
129 BNT162b2 was administered to children aged 5-11 years. The dosage of CoronaVac was 0.5 mL (600  
130 SU, equivalent to 3 µg, of inactivated SARS-CoV-2 virus as antigen) for all ages.

131 Vaccine recipients were monitored for 30 mins after each injection and reported the types, duration,  
132 and severity of adverse reactions (ARs) in a diary by an online or paper format for 7 days after  
133 vaccination. Peripheral blood was obtained before the first dose, second dose, 7-43 days after the  
134 second dose and 14-49 days after the third dose (if any) for measuring the serological antibody  
135 responses. The SARS-CoV-2 S receptor-binding domain (S-RBD) IgG enzyme linked immunosorbent  
136 assay (ELISA) (Chondrex Inc, Redmond, USA) and surrogate virus neutralization test (sVNT)  
137 (GenScript, New Jersey, USA) performed in our laboratory on the serum isolated from blood samples  
138 of patients had been validated and described in our previous publication.(24) Levels of S-RBD IgG are

139 expressed as optical density (OD<sub>450</sub>). The cut-off considered as seroconversion was OD<sub>450</sub> ≥ 0.50, while  
140 values below would be inputted as 0.25.(25) Neutralizing antibodies against SARS-CoV-2 WT and  
141 Omicron BA.1 were evaluated by sVNT with inhibition percentages (%) as the readout.(26) The cut-  
142 off for positive neutralizing antibody inhibition was ≥ 30%, and values below 30% would be inputted  
143 as 10%. Data from healthy children and adolescents were retrieved from our previous publication and  
144 COVAC study for comparison to this NMD cohort.(27)

145 Social and contact avoidance was common during this study period when the HK Omicron wave  
146 occurred, particularly for vulnerable patients as neurological and respiratory complications surged  
147 rapidly.(28) Therefore, some NMD patients were only able to attend our vaccination research sites and  
148 provide blood samples at the time-point of 7-43 days after the second dose.

## 149 **2.4 Statistical Analysis**

150 Associations between the categorical variables (presence of medically complexity, history of past  
151 COVID-19 infection, influenza and COVID-19 vaccination) and intention of receiving COVID-19  
152 vaccination (i.e., have received or plan to receive *vs* do not plan to receive COVID-19 vaccination)  
153 were analyzed by the Fisher's exact test. Intention of receiving COVID-19 vaccination between  
154 January and April 2022 was compared by the Cochran's Q test. Additionally, reasons for receiving the  
155 COVID-19 vaccines in January and April 2022 were compared by the Fisher's exact test. S-RBD IgG  
156 levels and sVNT % inhibition against WT were compared between NMD patients and the healthy  
157 population, also between the two vaccine types, by the Mann-Whitney U test. Comparisons between  
158 the sVNT% inhibition level against WT and Omicron BA.1 for each patient were computed using the  
159 Wilcoxon matched-pairs signed-rank test.  $p < 0.05$  was considered statistically significant.  
160 Data analyses and graphing were performed using GraphPad Prism (version 9.3.1).



161 **2.5 Standard Protocol Approval, Registration and Patient Consent**

162 The NMD patient registry and COVAC were approved by the HKU/Hospital Authority HK West  
163 Cluster IRB Committee (UW19-356 and UW 21-157, respectively). Written informed consent was  
164 obtained from adult participants or legally authorized representatives of the child participants.

### 165 3 Results

166 Of the 136 patients in the HK NMD registry, 52 were sent invitations to complete the COVID-19  
167 vaccine hesitancy survey, while the others did not fulfill criteria due to age or cognitive delay. Most  
168 patients, which were 41 (78.8%) of the 52, completed both the first and follow-up surveys. Eighteen  
169 (43.9%) of 41 who filled the survey had spinal muscular atrophy (SMA), while 26 (63.4%) had  
170 complex medical needs, including wheelchair mobility, tube or gastrostomy tube feeding, ventilator  
171 use, or brace or spinal surgery for scoliosis (Supplementary Table 1).

172 Two or more family members vaccinated against COVID-19 was positively associated with a higher  
173 intention of vaccination (OR: 11.7, 95% CI: 1.81-75.1,  $p=0.010$ ) (Table 1). Patients who received an  
174 influenza vaccine in the last three consecutive years tended to have higher intention of receiving  
175 COVID-19 vaccines, albeit not reaching statistical significance (24 of 30 vs 5 of 11, or 80.0% vs 45.5%,  
176  $p=0.052$ ). The major reasons that the NMD patients favored COVID-19 vaccination included their  
177 hopes for preventing infection (26 of 40, or 65.0%), protecting their family (16, or 40.0%) and returning  
178 to normal life (14, or 35.0%) (Table 2). Their concerns regarding COVID-19 vaccination included  
179 adverse effects that could be potentially worse than the healthy population (9 of 41, 22.0%), safety (9,  
180 or 22.0%), suitability (6, or 14.6%), effects on current NMD treatments (4, or 9.8%) and reduced  
181 efficacy (4, or 9.8%) (Figure 1). There were also 5 (12.2%) of 41 patients who expressed that their  
182 intention of vaccination depended on the progress of the pandemic. Indeed, in April 2022, which was  
183 shortly after the peak of the Omicron wave in HK, more respondents had or planned to receive the  
184 COVID-19 vaccines than in January 2022 (97.6% vs 73.3%,  $p=0.003$ ) (Supplementary Table 2). Also,  
185 30 (73.2%) patients expressed their intention of receiving future boosters, if necessary, in April 2022  
186 (Supplementary Table 2). Twenty (48.8%) of 41 patients expressed a vaccination history/intention of  
187 vaccination for at least 1 dose of BNT162b2 (B) or CoronaVac (C) in April 2022 (Supplementary Table  
188 3).

189 Forty-eight patients were invited from the NMD patient registry to complete the reactogenicity and  
190 immunogenicity arm from June 2021 to April 2022, while the others were not recruited due to the age  
191 exclusion criterion. Twenty-two (45.8%) patients joined the study (Supplementary Table 4). Nine  
192 patients had DMD, 7 patients had SMA, 3 patients had congenital myopathy (CM) and 1 patient had  
193 Becker muscular dystrophy, chronic inflammatory demyelinating polyneuropathy (CIDP) or myotonic  
194 disorder. Fourteen (63.6%) were in the late ambulatory or wheelchair mobile stage. All 9 DMD patients  
195 were on corticosteroids (ranges of dosage: 10-30 mg/day or 0.30-0.74 mg/kg/day). Seven SMA patients  
196 were on nusinersen or risdiplam. One CIDP patient was on intravenous immunoglobulin therapy  
197 infused regularly (dosage: 2 g/kg/3months). There were 16 (72.7%) and 6 (27.3%) of 22 patients who  
198 received two doses of BNT162b2 (BB) or CoronaVac (CC), respectively. One case of CM and DMD  
199 each had COVID-19 before enrollment into the study, while 1 patient with SMA reported contracting  
200 COVID-19 3 weeks after the first dose, and all three patients fully recovered subsequently.

201 Pain at the injection site (BB: 3 of 6, 50.0%, 6 of 11, CC: 54.5%), fatigue (BB: 4 of 6, 66.7%, 5 of  
202 11, CC: 45.5%) and myalgia (BB: 1 of 6, 16.7%, 3 of 11, CC: 27.3%) were the commonest ARs. Most  
203 ARs were mild (75.5%, n=71/94). No severe adverse events, such as apparent NMD deterioration,  
204 hospitalization, life-threatening complications, disabilities or deaths occurred (Figure 2).

205 All 19 patients with NMDs seroconverted against WT after BB or CC (Figure 3a). NMD patients  
206 had similar antibody responses compared to healthy children and adolescents (ELISA-CC: 2.03 vs 1.59;  
207 ELISA-BB : 2.19 vs 2.86; sVNT-CC: 85.2% vs 83.2%) (Figure 3a; Figure 3b). Although after receiving  
208 CC, the group on corticosteroids had lower S-RBD IgG than those not on corticosteroids (OD450: 1.82  
209 vs 2.37, p=0.02), corticosteroids did not affect the seroconversion rate (Supplementary Table 5). There  
210 was lower neutralization against Omicron BA.1. The median sVNT inhibition against WT and  
211 Omicron BA.1 was 96.3% and 10.0% after BB (p=0.063) (Figure 3c), respectively, while it was 85.2%  
212 and 10.0% after CC (p<0.001) (Figure 3d).

## 213 4 Discussion

214 This study demonstrated COVID-19 vaccination in family members is highly influential on the  
215 intention of receiving the vaccines for pediatric patients with NMDs, and those who received either the  
216 mRNA-based or inactivated whole-virus vaccines did not encounter severe ARs and had antibody  
217 responses similar to their healthy counterparts. This is consistent with the notion that family decision  
218 and support are key factors on COVID-19 vaccination for pediatric populations, as several recent  
219 studies observed this finding for healthy adolescents and children with neurodevelopmental disorders.  
220 (23, 29, 30) Additionally, patients who received the influenza vaccines in the recent consecutive years  
221 tended towards having the greater intention of COVID-19 vaccination, and we speculate this was due  
222 to higher vaccine confidence and complacency.(14, 31) These patients with NMDs were highly  
223 concerned about becoming infected, which was their main underlying reason for receiving the COVID-  
224 19 vaccines. This information will be useful for patient counseling as they continued to raise questions  
225 in our clinic regarding the need for the third dose and subsequent boosters in the future.

226 This is the first study to investigate the safety of the novel COVID-19 vaccines in children with  
227 NMDs, which showed BNT162b2 and CoronaVac were well tolerated. There were similar profiles of  
228 ARs between pediatric patients with NMDs, our healthy cohort, as well as adolescents and adults with  
229 NMDs and multiple sclerosis who received two doses of BNT162b2 or mRNA-1273.(20, 27, 32, 33)  
230 This is also the first study to demonstrate the inactivated whole-virus COVID-19 vaccine, CoronaVac,  
231 is immunogenic in pediatric patients with NMDs. Antibody responses were robust, an observation  
232 which was consistent with adolescent and adult patients with NMDs and myasthenia gravis who were  
233 able to generate antibody responses against WT.(20, 21, 33) It is reassuring that even for pediatric  
234 patients with NMDs and on corticosteroids, all patients had successful seroconversion after at least two  
235 doses of BNT162b2 or CoronaVac, which was also observed in adolescent and adult patients who  
236 received BNT162b2.(20, 33) Additionally, there were no apparent interactions between the COVID-

237 19 vaccines and treatments for NMDs, and our cohort of patients did not encounter NMD-related  
238 complications or hospitalization.

239 Importantly, our study included immunogenicity data against Omicron, which was first detected in  
240 southern Africa and became the dominant strain that causes SARS-COV-2 infections since late  
241 2021.(34) Different studies showed reduced vaccine effectiveness (VE) of BNT162b2 and CoronaVac  
242 against infection or mild COVID-19 due to the Omicron variant, including children and adolescents.(7,  
243 8, 35, 36) Our findings revealed reduced neutralizing activity against Omicron BA.1 in pediatric  
244 patients with NMDs. As neutralization correlates with protective efficacy against symptomatic  
245 COVID-19, we expect breakthrough infections would be more common in NMD patients due to  
246 Omicron than pre-Omicron variants, similarly with the rest of the population. A recent study in HK  
247 indicated that the VE of BNT162b2 and CoronaVac against infection would be 55.0% after two doses  
248 of vaccination in adolescents.(37, 38) On the other hand, studies showed that T cell responses in  
249 vaccinated adults were preserved against the BA.1 variants,(39, 40) which is correlated with clinical  
250 protection against severe diseases.(41) Therefore, patients with NMDs should become vaccinated to  
251 attain protection against severe COVID-19. Further boosters may enhance neutralization responses  
252 against Omicron subvariants for maximal protection.

253 There were several limitations in this study. First, it was not possible for participants to be enrolled  
254 into a study with a blinded and randomized design because these patients are already hesitant to receive  
255 novel vaccines and restriction on their choice on the type of vaccine would be an additional deterrent.  
256 There can be potential selection bias because more older males favored BNT162b2. However, the  
257 current findings have more real-life applicability and reflect the reality of outcomes for patients who  
258 can choose between vaccines. Reactogenicity and immunogenicity results were not available for all  
259 the timepoints, as we encouraged patients to receive the vaccines as soon and conveniently as possible  
260 for protection from severe COVID-19. This is because informed choice and prompt preventative

261 treatment for overcoming a surging wave of infection-related deaths in high-risk patients during the  
262 peak of our pandemic period is paramount and should be respected. Finally, the small sample size  
263 limits the generalizability of the study conclusions, but these are directly applicable to an important  
264 group of patients with a rare disease and are at high risk of severe infection-related complications.  
265 These results greatly contribute to the currently available scientific evidence that serves as the basis  
266 for appropriate clinical practice recommendations and policy-making decisions for patients with  
267 NMDs.

268 Taken together, these present findings and overall evidence support the routine schedule of  
269 vaccination for patients with NMDs, and the dosages of immunosuppressives used for the treatment of  
270 NMDs in relation to the BNT162b2 and CoronaVac vaccines are inconsequential.(4) We recommend  
271 that counseling for these patients should incorporate these informative points and to include several  
272 close relatives, if possible, because their decisions appear to be strongly influential towards vaccine  
273 hesitancy. Reassurance by reminding the patients about their tolerance to other vaccines, such as  
274 influenza, can also be considered. Future research is required to confirm that these counseling  
275 techniques are effective on addressing vaccine hesitancy. Additionally, as high as 26.8% (11 of 41) of  
276 our patients who completed the primary series have already expressed reluctance towards boosters in  
277 April 2022. Questions remain in terms of the safety, efficacy, long-lasting T cell immunity and  
278 durability of booster doses against other emerging variants,(42) such as Omicron BA2.75, BA.5, XBB,  
279 BQ1.1 and BF.7 for these patients. Finally, innovative aerosolized vaccines are under development that  
280 aim to induce mucosal immunity and thereby reduce viral transmission.(43) This method of inhibiting  
281 the initial step of infection offers a pathway towards ending the pandemic, which would be most  
282 promising if such route of immunization can be achieved for as many individuals as possible. Whether  
283 these aerosolized vaccines are effective for NMD patients, who have impaired respiratory function and  
284 inspiratory lung volumes, is intriguing and should be studied further.

285 **5 Tables**

286 Table 1: Factors associated with intention of receiving COVID-19 vaccination in patients with  
 287 neuromuscular diseases in January 2022.

	Have received or plan to receive vaccination (n=30)	Do not plan to receive vaccination (n=11)	<i>p</i> -values
Mean age (SD)	14.0 (3.4)	13.4 (3.3)	0.648
Female	15 (50.0)	3 (27.3)	0.291
Two or more family members are vaccinated against COVID-19 <sup>^</sup>	28 (93.3)	6 (54.5)	0.010*
Received the influenza vaccine in the previous year	22 (73.3)	5 (45.5)	0.140
Received the influenza vaccine in the last three continuous years	24 (80.0)	5 (45.5)	0.052
Know someone diagnosed with COVID-19	0 (0)	2 (18.2)	-
Previously completed compulsory COVID-19 testing	1 (3.3)	3 (27.3)	0.052
Wheelchair-mobile	16 (53.3)	6 (54.5)	1.000
Nasogastric or PEG tube feeding use	2 (6.7)	2 (18.2)	0.288
Ventilator support	10 (33.3)	4 (36.4)	1.000
Using spinal brace or had spinal surgery	7 (23.3)	1 (9.1)	0.412
Presence of one type of disability	7 (23.3)	5 (45.5)	0.247
Presence of two or more type of disabilities	11 (36.7)	3 (27.3)	0.719

288 SD= standard deviation, PEG= percutaneous endoscopic gastrostomy

289 <sup>^</sup>odds ratio is presented for those with significant association according to the Fisher's exact test

290 \**p*<0.05

291 Odds ratio= 11.7, 95% confidence interval: 1.81-75.1

292 Table 2: Major reasons for receiving COVID-19 vaccination in patients with neuromuscular diseases

	January 2022	April 2022	
	No. (%)	No. (%)	<i>p</i> -values
Planning to vaccinate/ already vaccinated	n=30	n=40	
Worried to be infected	17 (56.7)	26 (65.0)	0.620
To return full-scale face-to-face teaching	16 (53.3)	16 (40.0)	0.335
To protect their family	17 (56.7)	14 (35.0)	0.091
To return to normal life	19 (63.3)	13 (32.5)	0.015*
I think I am high risk group of COVID-19	7 (23.3)	12 (30.0)	0.596
Because people around me received vaccination	5 (16.7)	11 (27.5)	0.391
I am tired of the social distancing policies	9 (30.0)	10 (25.0)	0.787
I want to socialize with large groups of friends	3 (10.0)	10 (25.0)	0.132
I want to socialize with participate in large-scale events	2 (6.7)	9 (22.5)	0.100
I want to travel	14 (46.7)	8 (20.0)	0.022*
I want to play sports at school with friends or in a competition without wearing mask	11 (36.7)	7 (17.5)	0.098
To play music safely E.g.: wind instruments, band, choir	6 (20.0)	7 (17.5)	1.000
I want to join study tours E.g.: day trip, school visits or other extra-curricular activities	12 (40.0)	5 (12.5)	0.011*

293 \**p*<0.05



294 **6 Figure captions**

295 Figure 1: Major concerns about receiving COVID-19 vaccination in patients with neuromuscular  
296 diseases, AEs=adverse effects.

297 The three commonest concerns from patients with neuromuscular diseases were having a higher chance  
298 of AEs compared to healthy individuals (22.0%), safety (22.0%) and suitability (14.3%).

299 Figure 2: Reactogenicity for patients with neuromuscular diseases

300 Pain at injection site, fatigue and myalgia were the three commonest adverse reactions (ARs). Most  
301 ARs were mild. No patient reported any of the following symptoms within 7 days after vaccination:  
302 pruritis at injection site, reduced appetite or sore throat. There were no vaccine-related severe adverse  
303 events, such as hospitalizations, life-threatening complications, disabilities or deaths. B, 1 dose of  
304 BNT162b2; BB, 2 doses of BNT162b2; C, 1 dose of CoronaVac; CC, 2 doses of CoronaVac; BBB, 3  
305 dose of BNT162b2; CCC, 3 doses of CoronaVac; CCB, 2 doses of CoronaVac and 1 dose of  
306 BNT162b2.

307 Figure 3: Immunogenicity of BNT162b2 and CoronaVac for patients with neuromuscular diseases

308 Antibody responses were determined before the first dose, second dose, 7-43 days after the second  
309 dose and 14-49 days after the third dose of BNT162b2 or CoronaVac in patients with neuromuscular  
310 diseases (NMDs) (n=19). Three patients who had COVID-19 infection were excluded from the final  
311 analysis. Immunogenicity data from healthy children and adolescents used for comparisons with  
312 patients with NMDs were retrieved from our previous publication and COVAC study.(27) (a) and (b)  
313 All patients with NMDs successfully seroconverted by enzyme linked immunosorbent assay (ELISA)  
314 against wildtype SARS-CoV-2 virus (WT) after receiving two doses of BNT162b2 and CoronaVac.  
315 These patients showed similar antibody responses when compared to the healthy children and

316 adolescents. (c) and (d) surrogate virus neutralization test (sVNT) after BNT162b2 and CoronaVac  
317 was significantly lower against the SARS-CoV-2 Omicron BA.1 variant compared to WT. (c) The  
318 median % of inhibition level in the BB group was lower at 10.0% for Omicron BA.1 than WT at 96.3%  
319 ( $p>0.05$ ). (d) The median % of inhibition level in the CC group was lower at 10.0% for Omicron BA.1  
320 than WT at 85.2% ( $p<0.001$ ). B, 1 dose of BNT162b2; BB, 2 doses of BNT162b2; C, 1 dose of  
321 CoronaVac; CC, 2 doses of CoronaVac; BBB, 3 dose of BNT162b2; CCC, 3 doses of CoronaVac;  
322 CCB, 2 doses of CoronaVac and 1 dose of BNT162b2. BNT162b2 was represented as blue while  
323 CoronaVac was represented as orange color. Patients with NMDs using corticosteroids (deflazacort or  
324 prednisolone) daily were indicated as square dots in (c) & (d). \* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ ,  
325 \*\*\*\* $p<0.0001$ ) or NS (not significant).

326 **7 Conflict of Interest**

327 All authors declare that there is no conflict of interest.

328 **8 Author Contributions**

329 Michael Kwan Leung Yu was involved in the recruitment, performing the statistical analysis,  
330 interpretation of results and drafting this manuscript.

331 Sophelia Hoi Shan Chan was involved in the recruitment, clinical care, interpretation of results and  
332 drafting this manuscript.

333 Samuel Cheng was involved in conducting the ELISA and sVNT assay as well as the interpretation of  
334 results.

335 Daniel Leung was involved in the recruitment, study design, interpretation of results and drafting this  
336 manuscript.

337 Sau Man Chan was involved in the recruitment, study design and clinical care.

338 Amy Suen Ka Yan was involved in the study administrative procedures.

339 Wilfred Hing Sang Wong was involved in supervising the statistical analysis.

340 Malik Peiris was involved in supervising the ELISA and sVNT assay as well as the interpretation of  
341 results.

342 Yu-Lung Lau was the principal investigator of this project and was involved in the recruitment, study  
343 design, clinical care, interpretation of results and drafting this manuscript.

344 Jaime S Rosa Duque was involved in the recruitment, study design, clinical care, interpretation of  
345 results and drafting this manuscript.

## 346 **9 Funding**

347 This study was funded by the Health Bureau of the Government of Hong Kong, COVID19F02,  
348 COVID19F10 and COVID19F12.

## 349 **10 Acknowledgements**

350 This work was supported by the research grant COVID19F02, COVID19F10, and COVID19F12  
351 from the Health Bureau of the Government of Hong Kong. We thank Dr. Davy Chun-Wai Lee and Mr.  
352 Koon-Wing Chan at the Department of Paediatrics and Adolescent Medicine, LKS Faculty of  
353 Medicine, HKU for their laboratory management of the collected blood samples.

354 **11 References**

- 355 1. WHO Coronavirus (COVID-19) Dashboard: World Health Organisation; 2022 [Available  
356 from: <https://covid19.who.int/>.
- 357 2. Khetan AK, Yusuf S, Lopez-Jaramillo P, Szuba A, Orlandini A, Mat-Nasir N, et al. Variations  
358 in the financial impact of the COVID-19 pandemic across 5 continents: A cross-sectional, individual  
359 level analysis. *EClinicalMedicine*. 2022;44:101284.
- 360 3. : Johns Hopkins Coronavirus Resource Center; [Available from:  
361 <https://coronavirus.jhu.edu/map.html>.
- 362 4. Society WM. COVID-19 and people with neuromuscular disorders: World Muscle Society  
363 position and advice April 23rd, 2022, 8th Update 2021 [Available from:  
364 [https://www.worldmusclesociety.org/news/view/covid-19-and-people-with-neuromuscular-disorders-  
365 world-muscle-society-position-and-advice](https://www.worldmusclesociety.org/news/view/covid-19-and-people-with-neuromuscular-disorders-world-muscle-society-position-and-advice).
- 366 5. Veneti L, Berild JD, Watle SV, Starrfelt J, Greve-Isdahl M, Langlete P, et al. Vaccine  
367 effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2  
368 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022. *medRxiv*.  
369 2022:2022.03.24.22272854.
- 370 6. Fleming-Dutra KE, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi EK, et al.  
371 Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection  
372 in Children and Adolescents During Omicron Predominance. *JAMA*. 2022;327(22):2210-9.
- 373 7. Jara A, Undurraga EA, Zubizarreta JR, Gonzalez C, Acevedo J, Pizarro A, et al. Effectiveness  
374 of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. *Nat*  
375 *Med*. 2022;28(7):1377-80.

- 376 8. Florentino PTV, Alves FJO, Cerqueira-Silva T, Oliveira VA, Junior JBS, Jantsch AG, et al.  
377 Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron  
378 period. *Nat Commun.* 2022;13(1):4756.
- 379 9. Rosa Duque JS, Leung D, Yip KM, Lee DHL, So H-k, Wong WHS, et al. Effectiveness of  
380 BNT162b2 and CoronaVac against pediatric COVID-19-associated hospitalization and moderate-to-  
381 severe disease. *Cell Rep Med* (in press). 2022.
- 382 10. McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al. Vaccine  
383 effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong  
384 Kong: a population-based observational study. *The Lancet Infectious Diseases.* 2022;22(10):1435-43.
- 385 11. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed  
386 by Sinovac.: World Health Organization; 2021.
- 387 12. Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2,  
388 under emergency use listing: interim guidance. 2021.
- 389 13. Mallapaty S, Callaway E, Kozlov M, Ledford H, Pickrell J, Van Noorden R. How COVID  
390 vaccines shaped 2021 in eight powerful charts. *Nature.* 2021;600(7890):580-3.
- 391 14. Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. *Nat Med.*  
392 2021;27(8):1338-9.
- 393 15. Handberg C, Werlauff U, Hojberg AL, Knudsen LF. Impact of the COVID-19 pandemic on  
394 biopsychosocial health and quality of life among Danish children and adults with neuromuscular  
395 diseases (NMD)-Patient reported outcomes from a national survey. *PLoS One.* 2021;16(6):e0253715.
- 396 16. Wasilewska E, Sobierajska-Rek A, Sledzinska K, Malgorzewicz S, Jassem E, Wierzba J.  
397 Morbidity, Clinical Course and Vaccination against SARS-CoV-2 Virus in Patients with Duchenne  
398 Muscular Dystrophy: A Patient Reported Survey. *Int J Environ Res Public Health.* 2021;19(1).

- 399 17. Bertran Recasens B, Rubio MA. Neuromuscular Diseases Care in the Era of COVID-19. Front  
400 Neurol. 2020;11:588929.
- 401 18. Zivkovic SA, Gruener G, Narayanaswami P, Quality A, Patient Safety C. Doctor-Should I get  
402 the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders.  
403 Muscle Nerve. 2021;63(3):294-303.
- 404 19. COVID-19 and people with neuromuscular disorders:  
405 World Muscle Society advice - Vaccines and Therapeutics: World Muscle Society; 2022 [Available  
406 from: [https://www.worldmusclesociety.org/news/view/covid-19-and-people-with-neuromuscular-](https://www.worldmusclesociety.org/news/view/covid-19-and-people-with-neuromuscular-disorders-world-muscle-society-advice-vaccines)  
407 [disorders-world-muscle-society-advice-vaccines](https://www.worldmusclesociety.org/news/view/covid-19-and-people-with-neuromuscular-disorders-world-muscle-society-advice-vaccines).
- 408 20. Demonbreun AR, Velez MP, Saber R, Ryan DT, Sancilio A, McDade TW, et al. mRNA  
409 intramuscular vaccination produces a robust IgG antibody response in advanced neuromuscular  
410 disease. Neuromuscul Disord. 2021.
- 411 21. Reyes-Leiva D, Lopez-Contreras J, Moga E, Pla-Junca F, Lynton-Pons E, Rojas-Garcia R, et  
412 al. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia  
413 Gravis. Neurol Neuroimmunol Neuroinflamm. 2022;9(4).
- 414 22. Yu MKLW, W. H. S.; Gao, Y.; Rosa Duque, J. S.; Chan, G. C. F.; Chan, S. H. S.. Establishment  
415 of Hong Kong Neuromuscular Disorder Patient Registry. Hong Kong Journal of Paediatrics.  
416 2022;27(1):80.
- 417 23. Wong WHS, Leung D, Chua GT, Duque JSR, Peare S, So HK, et al. Adolescents' attitudes to  
418 the COVID-19 vaccination. Vaccine. 2022.
- 419 24. Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, et al. Serological assays for severe  
420 acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020;25(16).

- 421 25. Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, et al. Neutralizing  
422 antibody titres in SARS-CoV-2 infections. *Nat Commun.* 2021;12(1):63.
- 423 26. Perera R, Ko R, Tsang OTY, Hui DSC, Kwan MYM, Brackman CJ, et al. Evaluation of a  
424 SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat,  
425 and Hamster Sera. *J Clin Microbiol.* 2021;59(2).
- 426 27. Rosa Duque JS, Wang X, Leung D, Cheng SMS, Cohen CA, Mu X, et al. Immunogenicity and  
427 reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. *Nat*  
428 *Commun.* 2022;13(1):3700.
- 429 28. Tso WWY, Kwan MYW, Wang YL, Leung LK, Leung D, Chua GT, et al. Severity of SARS-  
430 CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and  
431 parainfluenza infections. *Emerg Microbes Infect.* 2022;11(1):1742-50.
- 432 29. Ali M, Proma TS, Tasnim Z, Islam MA, Urmi TA, Ahmed S, et al. Parental COVID-19 vaccine  
433 hesitancy for children with neurodevelopmental disorders: a cross-sectional survey. *Trop Med Health.*  
434 2022;50(1):24.
- 435 30. Lazarus JV, Wyka K, White TM, Picchio CA, Rabin K, Ratzan SC, et al. Revisiting COVID-  
436 19 vaccine hesitancy around the world using data from 23 countries in 2021. *Nat Commun.*  
437 2022;13(1):3801.
- 438 31. Oduwole EO, Pienaar ED, Mahomed H, Wiysonge CS. Current tools available for investigating  
439 vaccine hesitancy: a scoping review protocol. *BMJ Open.* 2019;9(12):e033245.
- 440 32. Briggs FBS, Mateen FJ, Schmidt H, Currie KM, Siefers HM, Crouthamel S, et al. COVID-19  
441 Vaccination Reactogenicity in Persons With Multiple Sclerosis. *Neurol Neuroimmunol Neuroinflamm.*  
442 2022;9(1).



- 443 33. Iwayama H, Ishihara N, Kawahara K, Madokoro Y, Togawa Y, Muramatsu K, et al. Early  
444 immunological responses to the mRNA SARS-CoV-2 vaccine in patients with neuromuscular  
445 disorders. *Front Immunol.* 2022;13:996134.
- 446 34. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic  
447 expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature.* 2022;603(7902):679-86.
- 448 35. Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al. BNT162b2  
449 Protection against the Omicron Variant in Children and Adolescents. *N Engl J Med.*  
450 2022;386(20):1899-909.
- 451 36. Higdon MM, Baidya A, Walter KK, Patel MK, Issa H, Espie E, et al. Duration of effectiveness  
452 of vaccination against COVID-19 caused by the omicron variant. *Lancet Infect Dis.* 2022;22(8):1114-  
453 6.
- 454 37. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron extensively  
455 but incompletely escapes Pfizer BNT162b2 neutralization. *Nature.* 2022;602(7898):654-6.
- 456 38. Cheng SMS, Mok CKP, Leung YWY, Ng SS, Chan KCK, Ko FW, et al. Neutralizing  
457 antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous  
458 CoronaVac or BNT162b2 vaccination. *Nat Med.* 2022;28(3):486-9.
- 459 39. Naranbhai V, Nathan A, Kaseke C, Berrios C, Khatri A, Choi S, et al. T cell reactivity to the  
460 SARS-CoV-2 Omicron variant is preserved in most but not all individuals. *Cell.* 2022;185(6):1041-51  
461 e6.
- 462 40. Gao Y, Cai C, Grifoni A, Muller TR, Niessl J, Olofsson A, et al. Ancestral SARS-CoV-2-  
463 specific T cells cross-recognize the Omicron variant. *Nat Med.* 2022;28(3):472-6.
- 464 41. Moss P. The T cell immune response against SARS-CoV-2. *Nat Immunol.* 2022;23(2):186-93.

465 42. Canetti M, Barda N, Gilboa M, Indenbaum V, Asraf K, Gonen T, et al. Six-Month Follow-up  
466 after a Fourth BNT162b2 Vaccine Dose. *N Engl J Med.* 2022.


467 43. Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, et al. Heterologous AD5-nCOV plus CoronaVac versus  
468 homologous CoronaVac vaccination: a randomized phase 4 trial. *Nat Med.* 2022;28(2):401-9.

469





470 **12 Data Availability Statement**


471 The original contributions presented in the study are included in the article/supplementary material,  
472 further inquiries can be directed to the corresponding author/s.

# Concerns about COVID-19 vaccines/ reasons against vaccination (n=41)









Visit 1 (Baseline blood sampling + Dose 1): June 2021 to April 2022  
 Visit 2 (Post-dose 1 blood sampling + Dose 2): 14 – 42 days from Visit 1  
 Visit 3 (Post-dose 2 blood sampling): 7-43 days from visit 2  
 Dose 3: 28 -267 days from Visit 2 , 4 patients took 3<sup>rd</sup> dose during Visit 3  
 Post dose 3 blood sampling: 14-49 days from dose 3

\*One patient excluded from blood-taking due to aged <3 years old  
 ^Blood sampling was not able to obtained for one patient

Table 1: Factors associated with intention of receiving COVID-19 vaccination in patients with neuromuscular diseases in January 2022

	Have received or plan to receive vaccination (n=30)	Do not plan to receive vaccination (n=11)	<i>p</i> -values
Mean age (SD)	14.0 (3.4)	13.4 (3.3)	0.648
Female	15 (50.0)	3 (27.3)	0.291
Two or more family members are vaccinated against COVID-19 <sup>^</sup>	28 (93.3)	6 (54.5)	0.010*
Received the influenza vaccine in the previous year	22 (73.3)	5 (45.5)	0.140
Received the influenza vaccine in the last three continuous years	24 (80.0)	5 (45.5)	0.052
Know someone diagnosed with COVID-19	0 (0)	2 (18.2)	-
Previously completed compulsory COVID-19 testing	1 (3.3)	3 (27.3)	0.052
Wheelchair-mobile	16 (53.3)	6 (54.5)	1.000
Nasogastric or PEG tube feeding use	2 (6.7)	2 (18.2)	0.288
Ventilator support	10 (33.3)	4 (36.4)	1.000
Using spinal brace or had spinal surgery	7 (23.3)	1 (9.1)	0.412
Presence of one type of disability	7 (23.3)	5 (45.5)	0.247
Presence of two or more type of disabilities	11 (36.7)	3 (27.3)	0.719

SD= standard deviation, PEG= percutaneous endoscopic gastrostomy

<sup>^</sup>odds ratio is presented for those with significant association according to the Fisher's exact test

\**p*<0.05

Odds ratio= 11.7, 95% confidence interval: 1.81-75.1



Table 2: Major reasons for receiving COVID-19 vaccination in patients with neuromuscular diseases

	January 2022	April 2022	
	No. (%)	No. (%)	<i>p</i> -values
Planning to vaccinate/ already vaccinated	n=30	n=40	
Worried to be infected	17 (56.7)	26 (65.0)	0.620
To return full-scale face-to-face teaching	16 (53.3)	16 (40.0)	0.335
To protect their family	17 (56.7)	14 (35.0)	0.091
To return to normal life	19 (63.3)	13 (32.5)	0.015*
I think I am high risk group of COVID-19	7 (23.3)	12 (30.0)	0.596
Because people around me received vaccination	5 (16.7)	11 (27.5)	0.391
I am tired of the social distancing policies	9 (30.0)	10 (25.0)	0.787
I want to socialize with large groups of friends	3 (10.0)	10 (25.0)	0.132
I want to socialize with participate in large-scale events	2 (6.7)	9 (22.5)	0.100
I want to travel	14 (46.7)	8 (20.0)	0.022*
I want to play sports at school with friends or in a competition without wearing mask	11 (36.7)	7 (17.5)	0.098
To play music safely E.g.: wind instruments, band, choir	6 (20.0)	7 (17.5)	1.000
I want to join study tours E.g.: day trip, school visits or other extra-curricular activities	12 (40.0)	5 (12.5)	0.011*

\* $p < 0.05$

### Concerns about COVID-19 vaccines/ reasons against vaccination (n=41)




Figure 1: Major concerns about receiving COVID-19 vaccination in patients with neuromuscular diseases

AEs=adverse effects

The three commonest concerns from patients with neuromuscular diseases were having a higher chance of AEs compared to healthy individuals (22.0%), safety (22.0%) and suitability (14.3%).






Figure 3: Immunogenicity of BNT162b2 and CoronaVac for patients with neuromuscular diseases

Antibody responses were determined before the first dose, second dose, 7-43 days after the second dose and 14-49 days after the third dose of BNT162b2 or CoronaVac in patients with neuromuscular diseases (NMDs) (n=19). Three patients who had COVID-19 infection were excluded from the final analysis. Immunogenicity data from healthy children and adolescents used for comparisons with patients with NMDs were retrieved from our previous publication and COVAC study.<sup>27</sup> (a) and (b) All patients with NMDs successfully seroconverted by enzyme linked immunosorbent assay (ELISA) against wildtype SARS-CoV-2 virus (WT) after receiving two doses of BNT162b2 and CoronaVac. These patients showed similar antibody responses when compared to the healthy children and adolescents. (c) and (d) surrogate virus neutralization test (sVNT) after BNT162b2 and CoronaVac was significantly lower against the SARS-CoV-2 Omicron BA.1 variant compared to WT. (c) The median % of inhibition level in the BB group was lower at 10.0% for Omicron BA.1 than WT at 96.3% ( $p > 0.05$ ). (d) The median % of inhibition level in the CC group was lower at 10.0% for

Omicron BA.1 than WT at 85.2% ( $p < 0.001$ ). B, 1 dose of BNT162b2; BB, 2 doses of BNT162b2; C, 1 dose of CoronaVac; CC, 2 doses of CoronaVac; BBB, 3 dose of BNT162b2; CCC, 3 doses of CoronaVac; CCB, 2 doses of CoronaVac and 1 dose of BNT162b2. BNT162b2 was represented as blue while CoronaVac was represented as orange color. Patients with NMDs using corticosteroids (deflazacort or prednisolone) daily were indicated as square dots in (c) & (d). \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ ) or NS (not significant).

Supplementary Table 1: Demographic and clinical characteristics of the patients with neuromuscular diseases in COVID-19 vaccine hesitancy survey arm of the study

	N/mean	%/SD
Demographics		
Age (years)	13.8	3.4
Female	18	43.9
Breakdown of NMDs		
Spinal muscular atrophy	18	43.9
5q type I	2	4.9
5q type II	10	24.4
5q type III	5	12.2
Non-5q spinal muscular atrophy	1	2.4
Dystrophinopathy	6	14.6
Duchenne muscular dystrophy	4	9.8
Becker muscular dystrophy	2	4.9
Congenital myopathy	5	12.2
Congenital muscular dystrophy	4	9.8
Peripheral neuropathies	2	4.9
Facioscapulohumeral muscular dystrophy	2	4.9
Myotonic disorder	2	4.9
Other NMDs <sup>^</sup>	2	4.9
Physical conditions		
Wheelchair-mobile	22	53.7
Nasogastric tube or PEG tube feeding use	4	9.8
Ventilator support	14	34.1
Using spinal brace or had spinal surgery	8	19.5

<sup>^</sup>Congenital myasthenic syndrome and ocular myasthenia gravis

NMDs= neuromuscular diseases, PEG= percutaneous endoscopic gastrostomy, SD= standard deviation, N= numbers

Supplementary Table 2: Intention of COVID-19 vaccination in patients with neuromuscular diseases in January and April 2022

Intention of COVID-19 vaccination	January 2022	April 2022	<i>p</i> -values
Have vaccinated/ planning to vaccinate	30 (73.2)	40 (97.6)	
Do not plan to vaccinate	11 (26.8)	1 (2.4)	
Total	41	41	0.003**
Will continue to receive future boosters, if any?			
Yes	26 (63.4)	30 (73.2)	
No	15 (36.6)	11 (26.8)	
Total	41	41	0.477

Data presented as number (%)

\*\* $p < 0.01$

Supplementary Table 3: Preference on COVID-19 vaccines in patients with neuromuscular diseases

Types of vaccines	January 2022			April 2022		
	Planning to receive	Already vaccinated	Total	Planning to receive	Already vaccinated	Total
BNT162b2	5 (33.3)	14 (93.3)	19 (46.3)	3 (100.0)	17 (45.9)	20 (48.8)
CoronaVac	8 (53.3)	1 (6.7)	9 (22.0)	0 (0.0)	20 (54.1)	20 (48.8)
Undecided	2 (13.3)	0 (0.0)	2 (4.9)	0 (0.0)	0 (0.0)	0 (0.0)
Do not plan to vaccinate	-	-	11 (26.8)	-	-	1 (2.4)
Total	15	15	41	3	37	41

Data presented as number (%)

Supplementary Table 4: Demographic and clinical characteristics of the patients with neuromuscular diseases in the COVID-19 vaccine reactogenicity and immunogenicity arm of the study

Patient	NMD type	Age (years)	Sex	Ambulatory status	Treatment	Dosage	Dose 1 & 2	Dose 3	COVID-19 infection
1	CIDP	16-20	Male	Independent walker	IVIG	2 g/kg/3months	BNT162b2	N/A	N
2	DMD	11-15	Male	Late ambulatory	Prednisolone	0.42 mg/kg/day	BNT162b2	BNT162b2	N
3	DMD	11-15	Male	Wheelchair mobile	Deflazacort	0.64 mg/kg/day	BNT162b2	N/A	N
4	CM	11-15	Female	Independent walker	N/A	N/A	BNT162b2	N/A	Y, before 1 <sup>st</sup> dose
5	SMA	11-15	Male	Wheelchair mobile	Risdiplam	0.13 mg/kg/day	BNT162b2	N/A	N
6	SMA	6-10	Male	Independent walker	Nusinersen	N/A	BNT162b2	BNT162b2	N
7	DMD	11-15	Male	Late ambulatory	Prednisolone	0.61 mg/kg/day	CoronaVac	CoronaVac	N
8	DMD	11-15	Male	Wheelchair mobile	Prednisolone	0.30 mg/kg/day	CoronaVac	N/A	N
9	DMD	0-5	Male	Independent walker	Deflazacort	0.64 mg/kg/day	CoronaVac	CoronaVac	N
10	SMA	6-10	Female	Wheelchair mobile	Nusinersen	0.56 mg/kg/day	CoronaVac	N/A	Y, after 1 <sup>st</sup> dose
11	SMA	0-5	Male	Wheelchair mobile	Nusinersen	0.56 mg/kg/day	CoronaVac	CoronaVac	N
12 <sup>^</sup>	CM	6-10	Female	Wheelchair mobile	N/A	N/A	CoronaVac	BNT162b2	N
13	DMD	6-10	Male	Late ambulatory	Deflazacort	0.74 mg/kg/day	CoronaVac	CoronaVac	N
14	SMA	0-5	Female	Wheelchair mobile	Nusinersen	0.83 mg/kg/4 months	CoronaVac	CoronaVac	N
15	DMD	11-15	Male	Wheelchair mobile	Deflazacort	0.67 mg/kg/day	CoronaVac	N/A	Y, before 1 <sup>st</sup> dose
16	MD	6-10	Female	Independent walker	Melatonin	5.45 mg/kg/day	CoronaVac	CoronaVac	N
17	DMD	<20	Male	Wheelchair mobile	Prednisolone	0.49 mg/kg/day	CoronaVac	CoronaVac	N
18*	SMA	11-15	Male	Independent walker	Nusinersen	0.38 mg/kg/4months	CoronaVac	N/A	N
19*	DMD	6-10	Male	Independent walker	Prednisolone	0.72 mg/kg/day	CoronaVac	N/A	N
20*	SMA	11-15	Female	Wheelchair mobile	Nusinersen	0.48 mg/kg/4months	CoronaVac	N/A	N
21*	BMD	11-15	Male	Independent walker	N/A	N/A	CoronaVac	CoronaVac	N
22*	CM	11-15	Female	Late ambulatory	N/A	N/A	CoronaVac	CoronaVac	N



BMD= Becker muscular dystrophy, CIDP= chronic inflammatory demyelinating polyneuropathy, CM= congenital myopathy, DMD= Duchenne muscular dystrophy, IVIG= intravenous immunoglobulins, MD= myotonic disorder, N/A= not applicable, SMA= spinal muscular atrophy

^Blood samples for immunogenicity assay before the first and after the third dose of COVID-19 vaccination

\*Blood samples for immunogenicity assay after the second dose of COVID-19 vaccination only

Supplementary Table 5: Comparison of immunogenicity for patients with neuromuscular diseases by corticosteroids use

Dosage	C	B	CC	BB	CCC/CCB	BBB
<b>ELISA OD450</b>						
CS user median (N)	0.25 (5)	0.87 (2)	1.82 (5)	1.82 (2)	2.26 (4)	3.04 (1)
Non-CS user median (N)	1.30 (2)	1.35 (3)	2.37 (8)	2.58 (3)	3.23 (6)	3.19 (1)
<i>p</i> -value	0.24	0.80	0.02*	0.20	0.07	N/A
<b>sVNT % inhibition</b>						
CS user median (N)	15.0 (5)	55.3 (2)	84.4 (5)	93.9 (2)	83.1 (4)	97.2 (1)
Non-CS user median (N)	37.6 (2)	50.5 (3)	89.3 (8)	96.3 (3)	96.5 (6)	97.3 (1)
<i>p</i> -value	0.86	0.80	0.35	0.80	0.11	N/A

Data presented as median (number of patients in group)

B, 1 dose of BNT162b2; BB, 2 doses of BNT162b2; C, 1 dose of CoronaVac; CC, 2 doses of CoronaVac; BBB, 3 dose of BNT162b2; CCC, 3 doses of CoronaVac; CCB, 2 doses of CoronaVac and 1 dose of BNT162b2.

CS= corticosteroids, ELISA= enzyme linked immunosorbent assay, N/A= Not applicable,

OD= optical density, sVNT= surrogate virus neutralization test

\**p*<0.05


Supplementary Table 6: Immunogenicity of patients with neuromuscular diseases who had COVID-19 infection

Patient No.	Vaccine	Age	Sex	COVID-19 history	Pre-dose 1 ELISA OD450	Pre-dose 1 sVNT % inhibition	Dose 1 ELISA OD450	Dose 1 sVNT % inhibition	Dose 2 ELISA OD450	Dose 2 sVNT % inhibition
4	BB	11-15	F	6 weeks before dose 1	0.25	15	2.56	86.6	3.14	97.8
10	CC	6-10	F	3 weeks after dose 1	N/A	N/A	1.14	36.1	2.98	92.4
15	CC	11-15	M	1 month before dose 1	0.51	15	0.53	15	1.34	15

These patients were excluded from the main immunogenicity analyses

BB, 2 doses of BNT162b2; CC, 2 doses of CoronaVac

ELISA= enzyme linked immunosorbent assay, OD= optical density, sVNT= surrogate virus neutralization test



Supplementary Figure 1: Flow diagram of study participants

136 patients were screened from the patient registry. Fifty-two patients were invited to complete the hesitancy survey arm, and 48 patients were invited to join the reactogenicity and immunogenicity arm of the study. Forty-five patients completed the first hesitancy survey, and 41 (91.1%) of them completed both first and second surveys. For the reactogenicity and immunogenicity arm of the study, 22 patients joined and 17 were inoculated with BNT162b2 or CoronaVac at our HKU Community Vaccination Centers (CVCs) research site. These patients recorded adverse reactions in a 7-day diary system after vaccination for reactogenicity/safety analyses and had blood sampling. Additionally, 5 patients who received two doses of CoronaVac at nearby CVCs and had blood sampling after the second dose.